Imlunestrant clinical trials
Also written LY3484356.
ClinicalTrials.gov finds 21 studies for Imlunestrant. How that becomes 15 here
Every study that search finds has been read, to see whether and how it gives Imlunestrant. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 21Found by its intervention search · See all 21 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 15 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 21Give Imlunestrant to participants
- −6Give it beside what is tested
- 15Test it: the count on this site
Get an email when these change. Save the Imlunestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Sept 2025 · INLURIYO · NDA 218881 (FDA, Drugs@FDA)
- European Union
- 9 Jan 2026 · Inluriyo · EMEA/H/C/006184 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 4 |
| 2022 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 3
Eli Lilly and Company (12) · Dana-Farber Cancer Institute (1) · Fudan University (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Abemaciclib (3) · Carbamazepine (1) · Omeprazole (1) · Selinexor (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 3 most studied
New when their studies opened, with Imlunestrant beside them; studies of each.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test Imlunestrant, phase 3 first.
- Oct 2027A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerPhase 3 · Eli Lilly and Company
- Aug 2027A Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsPhase 1 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses Imlunestrant has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 15
- A Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsNot yet recruitingPhase 1Eli Lilly and CompanyNCT07918859Two tablet forms compared in healthy women, with food and omeprazoleWritten as Imlunestrant (Test)Report a problem
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingPhase 2Eli Lilly and CompanyNCT07287098Alone or with goserelin against tamoxifen, premenopausal womenWritten as ImlunestrantReport a problem
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227With abemaciclib and selinexor in ovarian and endometrial cancerWritten as ImlunestrantReport a problem
- Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07191717With abemaciclib against residual diseaseWritten as ImlunestrantReport a problem
- Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07410559With abemaciclib before surgery, guided by Ki67Written as Imlunestrant + abemaciclibReport a problem
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT04975308On the US labelAgainst standard endocrine therapy, alone or with abemaciclib (EMBER-3)Written as ImlunestrantReport a problem
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT04188548First-in-human, alone or combined (EMBER)Written as LY3484356Report a problem
- A Study of LY3484356 in Chinese Participants With Advanced Breast CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT05509790Dose finding in Chinese patientsWritten as LY3484356Report a problem
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05514054Adjuvant against standard endocrine therapy (EMBER-4)Written as ImlunestrantReport a problem
- A Study of Imlunestrant (LY3484356) in Female Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05444556Its effect on probe drugs in healthy womenWritten as ImlunestrantReport a problem
- A Study of LY3484356 in Healthy Female ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04840888Food and interacting drugs in healthy womenWritten as LY3484356Report a problem
- A Study of [¹⁴C]-LY3484356 in Healthy Female ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04991766Radiolabelled dose in healthy womenWritten as [¹⁴C]-LY3484356Report a problem
- A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver FunctionCompletedPhase 1Eli Lilly and CompanyNCT05440344Single dose across liver impairmentWritten as ImlunestrantReport a problem
- A Study of Imlunestrant (LY3484356) in Healthy WomenCompletedPhase 1Eli Lilly and CompanyNCT05509816Its effect on midazolamWritten as ImlunestrantReport a problem
- A Study of LY3484356 in Women With Breast Cancer Before Having SurgeryCompletedPhase 1Eli Lilly and CompanyNCT04647487Before surgery at three doses (EMBER-2)Written as LY3484356Report a problem
Behind its US label · 1 — the studies the FDA label of INLURIYO describes
From the Clinical Studies section of INLURIYO (2026-06), as openFDA has it. A study the site does not hold is left out.
Tested on its own · 5 — no other medicine in its arm
- A Study of LY3484356 in Chinese Participants With Advanced Breast CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT05509790Dose finding in Chinese patientsWritten as LY3484356Report a problem
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05514054Adjuvant against standard endocrine therapy (EMBER-4)Written as ImlunestrantReport a problem
- A Study of [¹⁴C]-LY3484356 in Healthy Female ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04991766Radiolabelled dose in healthy womenWritten as [¹⁴C]-LY3484356Report a problem
- A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver FunctionCompletedPhase 1Eli Lilly and CompanyNCT05440344Single dose across liver impairmentWritten as ImlunestrantReport a problem
- A Study of LY3484356 in Women With Breast Cancer Before Having SurgeryCompletedPhase 1Eli Lilly and CompanyNCT04647487Before surgery at three doses (EMBER-2)Written as LY3484356Report a problem
Tested with established drugs · 5 — they are given beside it
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingPhase 2Eli Lilly and CompanyNCT07287098Alone or with goserelin against tamoxifen, premenopausal womenWritten as ImlunestrantReport a problem
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT04975308On the US labelAgainst standard endocrine therapy, alone or with abemaciclib (EMBER-3)Written as ImlunestrantReport a problem
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT04188548First-in-human, alone or combined (EMBER)Written as LY3484356Report a problem
- A Study of Imlunestrant (LY3484356) in Female Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05444556Its effect on probe drugs in healthy womenWritten as ImlunestrantReport a problem
- A Study of Imlunestrant (LY3484356) in Healthy WomenCompletedPhase 1Eli Lilly and CompanyNCT05509816Its effect on midazolamWritten as ImlunestrantReport a problem
Tested in a combination · 5 — another drug in the study is under test too
- A Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsNot yet recruitingPhase 1Eli Lilly and CompanyNCT07918859Two tablet forms compared in healthy women, with food and omeprazoleWritten as Imlunestrant (Test)Report a problem
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227With abemaciclib and selinexor in ovarian and endometrial cancerWritten as ImlunestrantReport a problem
- Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07191717With abemaciclib against residual diseaseWritten as ImlunestrantReport a problem
- Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07410559With abemaciclib before surgery, guided by Ki67Written as Imlunestrant + abemaciclibReport a problem
- A Study of LY3484356 in Healthy Female ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04840888Food and interacting drugs in healthy womenWritten as LY3484356Report a problem
Beside a new treatment under test · 3 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Imlunestrant: Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783 1 · PRT13722 1 · STX-478 1
- A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast CancerRecruitingPhase 1Prelude Therapeutics IncorporatedNCT07905001Partner of new PRT13722 in one armWritten as ImlunestrantReport a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Partner of new tersolisibWritten as ImlunestrantReport a problem
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingPhase 1Eli Lilly and CompanyNCT05307705Partner of new LOXO-783 in one partWritten as ImlunestrantReport a problem
One option of several · 3 — a test or a strategy chooses among drugs
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingPhase 1/2RayzeBio, Inc.NCT06590857One endocrine choice beside new RYZ101Report a problem
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingPhase 1Eli Lilly and CompanyNCT07114601One standard therapy option beside new LY4257496Report a problem
- SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04923542One endocrine option beside abemaciclib and radiosurgeryReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- A Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsNov 5, 2026NCT07918859
Codes
What other systems call Imlunestrant · ClinicalTrials.gg INT001724
- MeSH (NLM) C000719756ImlunestrantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9CXQ3PF69UIMLUNESTRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q123582076imlunestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174042ImlunestrantOne source FDA
- DrugBank DB19043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719756 | Imlunestrant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9CXQ3PF69U | IMLUNESTRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123582076 | imlunestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174042 | Imlunestrant | One source FDA |
| DrugBank | DB19043 | — | One source Wikidata |
Also registered as imlunestrant tosylate (UNII F7UDT90EW5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.